Strategyanalysis of Bangladesh Pharmaceutical Industry
Table of Contents
Introduction: 1
Bangladeshi Pharmaceutical Industry: 2
Industry Analysis: 2 Competitive Force 1: Rivalry among Existing Firms 3 Competitive Force 2: Threat of New Entrants 3 Competitive Force 3: Threat of Substitute Products 3 Competitive Force 4: Bargaining Power of Buyers 4 Competitive Force 5: Bargaining Power of Suppliers 4
Competitive Strategy Analysis: 5 Cost Leadership: 5 Product Differentiation: 5
Corporate Strategy Analysis: 6
Conclusion:………………………………………………………………………………………………………7
Reference: 8
Introduction:
Bangladesh is one of the ten most populous countries in the world. It is also one of the poorest. Access to even the most basic healthcare provision remains very poor, despite the ongoing efforts of the government, aided by considerable international assistance. Adequate secondary or tertiary care is beyond the reach of all but a very few people. Government hospitals are often little more than clinics, and suffer from severe shortages of trained staff. There is growing private hospital sector, largely based in Dhaka, which caters to the well-off. It is in the private sector where the most advanced services are located, and where almost all the demand for the pharmaceutical market will be found.
Globally, political pressure for health care cost containment and reform have lead gradually to more favorable legislation and policies supporting increased utilization of generics. Many of the top generic companies who themselves are now huge global players have seized on the opportunities as wave of blockbuster patents expires. They have inspired confidence in generic drugs as high quality, therapeutic equivalents to the brand. Today the generics hold approximately 35% share of the total US market by volume and some are even out pacing the big Pharmaceutical companies in earnings performance. Indian companies are slowly but surely on the verge of penetrating this very lucrative market and yet Bangladeshi Pharmaceutical
Introduction: 1
Bangladeshi Pharmaceutical Industry: 2
Industry Analysis: 2 Competitive Force 1: Rivalry among Existing Firms 3 Competitive Force 2: Threat of New Entrants 3 Competitive Force 3: Threat of Substitute Products 3 Competitive Force 4: Bargaining Power of Buyers 4 Competitive Force 5: Bargaining Power of Suppliers 4
Competitive Strategy Analysis: 5 Cost Leadership: 5 Product Differentiation: 5
Corporate Strategy Analysis: 6
Conclusion:………………………………………………………………………………………………………7
Reference: 8
Introduction:
Bangladesh is one of the ten most populous countries in the world. It is also one of the poorest. Access to even the most basic healthcare provision remains very poor, despite the ongoing efforts of the government, aided by considerable international assistance. Adequate secondary or tertiary care is beyond the reach of all but a very few people. Government hospitals are often little more than clinics, and suffer from severe shortages of trained staff. There is growing private hospital sector, largely based in Dhaka, which caters to the well-off. It is in the private sector where the most advanced services are located, and where almost all the demand for the pharmaceutical market will be found.
Globally, political pressure for health care cost containment and reform have lead gradually to more favorable legislation and policies supporting increased utilization of generics. Many of the top generic companies who themselves are now huge global players have seized on the opportunities as wave of blockbuster patents expires. They have inspired confidence in generic drugs as high quality, therapeutic equivalents to the brand. Today the generics hold approximately 35% share of the total US market by volume and some are even out pacing the big Pharmaceutical companies in earnings performance. Indian companies are slowly but surely on the verge of penetrating this very lucrative market and yet Bangladeshi Pharmaceutical